product portfolio News
Most Popular product portfolio Story
CombinatoRx dumps RA program as data fails to add up
CombinatoRx has opted to abandon a development program for its rheumatoid arthritis therapy, CRx-150, after the latest set of trial data failed to demonstrate the kind of effectiveness needed to compete for that market. Researchers said that the therapy did demonstrate statistically significant responses for two key criteria in the trial, but failed to perform in a third.
"The level of activity observed with CRx-150 would not be competitive within the CombinatoRx product portfolio …
... Read more...Latest Headlines
- May 27, 2008
- May 27, 2008
- March 10, 2008
- October 1, 2007
- August 29, 2007
- June 28, 2007
- December 11, 2006
- November 20, 2006
- April 26, 2006
- March 12, 2006
- December 5, 2005
- July 12, 2005
- June 23, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
